A clinical-stage biotechnology company focused on developing oral small‑molecule therapies that target G protein‑coupled receptors (GPCRs), a large class of validated drug targets. Its pipeline includes treatments for metabolic, cardiovascular, and pulmonary diseases, with investor attention centere...
1 member of Congress has disclosed 1 trade in Structure Therapeutics Inc. (GPCR), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-10-04 | Thomas R Carper | sell | $1K – $15K |